News - Page 114 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article Psychedelic Bulletin: The Cost-Effectiveness of MDMA for PTSD; The Challenges Ahead for Psychedelic Medicine

Psychedelic Bulletin: The Cost-Effectiveness of MDMA for PTSD; The Challenges Ahead for Psychedelic Medicine

Post published:March 7, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Research Bulletin: February 2022

Psychedelic Research Bulletin: February 2022

Post published:March 7, 2022
Post category:Psychedelics Research Review

Read more about the article Field Trip Health and Cerebral Partner to Provide End-to-End Mental Health Care

Field Trip Health and Cerebral Partner to Provide End-to-End Mental Health Care

Post published:March 3, 2022
Post category:Press Release

Read more about the article MINDCURE Achieves Key Development Milestone for Novel Ibogaine Program

MINDCURE Achieves Key Development Milestone for Novel Ibogaine Program

Post published:March 2, 2022
Post category:Press Release

Read more about the article Red Light Holland Reports Fiscal Third Quarter Results

Red Light Holland Reports Fiscal Third Quarter Results

Post published:March 1, 2022
Post category:Press Release

Read more about the article Mydecine Reports Positive Pre-IND Meeting With FDA For MYCO-001 Smoking Cessation Study

Mydecine Reports Positive Pre-IND Meeting With FDA For MYCO-001 Smoking Cessation Study

Post published:March 1, 2022
Post category:Press Release

Numinus Wellness Announces Voting Results From its Annual General and Special Meeting of Shareholders

Post published:February 28, 2022
Post category:Press Release

Read more about the article Psychedelic Bulletin: Following the Money – How Much do Psychedelics Companies Spend on R&D?

Psychedelic Bulletin: Following the Money – How Much do Psychedelics Companies Spend on R&D?

Post published:February 28, 2022
Post category:Psychedelic Bulletin

Read more about the article HAVN Life Secures Purchase Order for Controlled Substance Sale to Revive Therapeutics Ltd. for Use in Clinical Research

HAVN Life Secures Purchase Order for Controlled Substance Sale to Revive Therapeutics Ltd. for Use in Clinical Research

Post published:February 24, 2022
Post category:Press Release

Read more about the article Entheon Biomedical Announces EBIQ-101 First-Patient Dose

Entheon Biomedical Announces EBIQ-101 First-Patient Dose

Post published:February 24, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.